Dear Mr. Zimmer,
After reading your article titled "How the Search for Covid-19 Treatments Faltered While Vaccines Sped Ahead", I would be remiss not to contact you regarding the drug Brilacidin currently just starting a phase 2 trial with a fast track designation. But, if you look at this drug"s history it has been a long, slow winding road for this company called Innovation Pharmaceuticals. You write in your article, "In February, Dr. Chanda and his colleagues began a different kind of search for a Covid-19 antiviral. They screened a library of 13,000 drugs, mixing each drug with cells and coronaviruses to see if they stopped infections." Brilicidin was one of a few drugs that passed with flying colors. When you research Brilicidin you will see the extensive in vitro lab testing given to this drug and positive outcomes, but no grant money or any type of assistance. You also state "Experts are particularly eager to see this data because molnupiravir may be effective in treating more than just Covid-19. This drug fits the bill. In April, scientists found that the drug could also treat mice infected with other coronaviruses that cause SARS and MERS giving it the potential for many other indications. {credit to Farrell90 for his research and comments on investorshub regarding quoted statements}
There is definitely a story here Mr. Zimmer, as this company has been beaten down, ignored, sued, and a favorite target for the shorters. Yet it continues to go it alone and survive. With a little help this drug has the potential to save thousands of lives. Hope you will find some time to do a little research and find it warrants a follow up article. Thank you for your time. Stew Goldstein
